Loading...
XJPX
8086
Market cap1.37bUSD
Oct 09, Last price  
1,319.00JPY
1D
-0.86%
1Q
-14.71%
Jan 2017
3.21%
Name

Nipro Corp

Chart & performance

D1W1MN
XJPX:8086 chart
P/E
15.93
P/S
0.33
EPS
82.80
Div yield, %
2.25%
Shrs. gr., 5y
2.45%
Rev. gr., 5y
7.71%
Revenues
660.54b
+2.47%
184,362,000,000172,113,000,000175,944,000,000177,829,000,000195,942,000,000212,013,000,000241,020,000,000300,752,000,000325,084,000,000366,650,000,000359,699,000,000395,397,000,000426,399,000,000442,516,000,000455,559,000,000494,789,000,000545,199,000,000586,785,000,000644,586,000,000660,538,000,000
Net income
13.50b
+164.06%
8,555,000,0004,454,000,0004,532,000,0007,252,000,0002,455,000,0004,585,000,00010,231,000,0002,861,000,00012,470,000,00019,718,000,00011,346,000,00011,830,000,00012,136,000,000-12,281,000,00014,210,000,00013,455,000,0004,575,000,00011,109,000,0005,114,000,00013,504,000,000
CFO
54.66b
-20.16%
14,488,000,0009,675,000,00018,851,000,00026,240,000,00021,799,000,00015,486,000,00022,593,000,00021,552,000,00027,981,000,00029,934,000,00033,472,000,00041,046,000,00041,362,000,00037,246,000,00066,093,000,00068,214,000,00010,395,000,00072,936,000,00068,461,000,00054,657,000,000
Dividend
Mar 30, 202720 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.

Related entities

Subsidiaries (5)
NIPRO EUROPE GROUP COMPANIES
NIPRO PHARMAPACKAGING INDIA PRIVATE LIMITED
Nipro Digital Technologies Europe
NIPRO MEDICAL EUROPE
Nipro PharmaPackaging International

Key people

Yoshihiko Sano
Chairman of the Board, Representative Director · since 2025
Tsuyoshi Yamazaki
President, Representative Director · since 2025
Takehito Yogo
Senior Managing Director, Chief Director of Administration Supervision & Management Planning · since 2023
Kenichi Nishida
Managing Director, Senior Chief Director of Pharmaceutical Production, Director of Pharmaceutical Business, President of Subsidiary · since 2023
Kazuhiko Sano
Managing Director, Chief Director of Facilities, Manager of Production Technology Center · since 2023
Keizo Maruyama
Executive Officer, Chief Director of Domestic Business in Main Domestic Product Development/Technical Sales Unit · since 2024
Ryo Matsunoshita
Executive Officer, Director of International Business Unit in Main Nipro Brand Sales Unit · since 2024
Goichi Miyazumi
Executive Officer, Director of Sub-Businesses in International Business Unit, Chief Director in Main Sales Unit · since 2024
Akio Shirasu
Executive Officer, Manager of Artificial Organ Development Center, Senior Director in Research Supervision Unit, Dir of Cardiopulmonary Artillery Product Develop, Tech Sales Unit · since 2024
Hideto Nakamura
Chief Director of Human Resources & General Affairs, Senior Director of Governance, Director · since 2021
Stephan Arnold
Executive Officer · since 2024
Kazuhiko Fujishima
Executive Officer, Dep Ch Dir of Domestic Production in Main Domestic Business Supervision Unit, Dep Ch Dir of International Production Business in Main International Business Unit · since 2024
Nozomu Fujita
Executive Officer, Deputy Director of Vascular Business Unit, Manager of Overseas Business Strategy Office · since 2022
Tsuyoshi Hashimoto
Executive Officer, Director of Sales Administration in Domestic Business Unit, Director of Business Strategy Office · since 2022
Koki Hatakeyama
Executive Officer, Deputy Chief Director in Main Stable Production & Crisis Unit, Director in Quality Assurance Unit · since 2024
Hisashi Hayashi
Executive Officer, Senior Chief Director of Governance, Director in Legal Unit, Director of the Examination Administration Unit · since 2024
Norihiro Hiejima
Executive Officer, Deputy Senior Director of Research Supervision Unit in Main Planning, Development and Technology Unit, Director of 5th Research and Development in 1st Unit · since 2024
Takumi Ikewaki
Executive Officer, Director in 2nd Mechatronics Design Unit, Deputy Manager of Production Technology Center · since 2022
Masayuki Ito
Executive Officer, Director of Business in SD Business Unit · since 2023
Masanobu Iwasa
Executive Officer, Director of Business in Main Pharma Packaging Business Unit · since 2024
IPO date
Feb 01, 1987
Employees
38,770
Domiciled in
JP
Incorporated in
JP
Headquarters & legal address
千里丘新町3番26号
⼤阪府 摂津市 566-8510
JP
Address
3-26, Senriokashinmachi
Settsu Osaka 566-8510
JP
Other language
NIPRO CORPORATION

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT